European Society for Medical Oncology Congress

In this video interview, Sara M. Tolaney, MD, MPH, of Dana-Farber Cancer Institute and Harvard Medical School, talks about overall survival data from MONALEESA-2 presented at the virtual ESMO Congress.

Sara M. Tolaney, MD, MPH, discussed “unprecedented results” from DESTINY-Breast03 presented at the virtual ESMO Congress in a video interview with Healio.

In this video, Sara M. Tolaney, MD, MPH, of Dana-Farber Cancer Institute and Harvard Medical School, discusses overall survival data from KEYNOTE-355 presented at the virtual ESMO Congress.

In a video interview, Sara M. Tolaney, MD, MPH, discussed the currently enrolling DESTINY-Breast09 trial presented at the virtual ESMO Congress.

The addition of ribociclib to front-line letrozole prolonged OS among postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer, results of the randomized phase 3 MONALEESA-2 trial showed.

The addition of nivolumab to chemotherapy showed durable benefit for treatment-naive patients with advanced gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma, 2-year data from the CheckMate 649 study showed.

In this video, Pasi A. Jänne, MD, PhD, director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School, discusses results from the IMpower010 study presented at ESMO 2021.

In this video, Pasi A. Jänne, MD, PhD, director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School, discusses results from the DESTINY-Lung01 study presented at ESMO 2021.

Treatment with [vic-]trastuzumab duocarmazine significantly improved PFS compared with physician’s choice of treatment in patients with pretreated locally advanced or metastatic HER2-positive breast cancer, according to phase 3 SYD985.002/TULIP trial data presented at the virtual ESMO Congress.

DESTINY-Breast03 data presented at the virtual ESMO Congress showed that trastuzumab deruxtecan significantly improved PFS compared with trastuzumab emtansine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.